Arrowstreet Capital
ITOS

Arrowstreet Capital’s iTeos Therapeutics ITOS Stock Holding History

Arrowstreet Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-41,511
Closed -$855K – 1368
2022
Q2 		$855K Buy
+41,511
New +$985K ﹤0.01% 969
2021
Q3 		– Sell
-9,560
Closed -$245K – 1725
2021
Q2 		$245K Buy
+9,560
New +$228K ﹤0.01% 1766

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Arrowstreet Capital's ITOS Position: Q3 2022 in Review

Arrowstreet Capital sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 41,511 shares — an estimated $855K sold.

Arrowstreet Capital first reported a position in ITOS in Q2 2021 and held it in 2 quarters. The position peaked at $855K in Q2 2022. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • Arrowstreet Capital reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 41,511 iTeos Therapeutics shares in Q3 2022, an estimated $855K.
  • Arrowstreet Capital first reported a position in iTeos Therapeutics in Q2 2021 and held it in 2 quarters.
  • Arrowstreet Capital's iTeos Therapeutics position peaked at $855K in Q2 2022.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.